The Boehringer Ingelheim and Lilly laboratories have launched a new treatment for type 2 diabetes patients who say it will facilitate the fulfillment of patients and help reduce cardiovascular mortality.
This has been explained by the two companies in a joint statement sent today in which they explain that the product is now available in Spain as a therapeutic alternative for this disease.
The new treatment combines melformin and opponent, the only oral antidiabetic that has demonstrated the reduction of cardiovascular mortality in patients with type 2 diabetes, the first cause of death among these patients.
The mixture of these two products must be administered in a single tablet twice a day, and this reduction in mortality has been demonstrated, the two companies say, in the EMPA-REG-OUTCOME study in patients of this disease.
"We help simplify the treatment regime to our diabetic patients who, in general, usually take multiple medications for other comorbidities such as arterial hypertension or cholesterol," says the endocrinologist and secretary of the Spanish Society of Endocrinology and Nutrition (SEEN), Sharona Azriel.EFE
